Mineralys Therapeutics, Inc. (MLYS) Misses Q4 EPS by 27c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q4 EPS of ($0.98), $0.27 worse than the analyst estimate of ($0.71).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Kaiser Aluminum names Fred Stephan as CEO, effective November 2026
• Beyond Air, Inc. (XAIR) files for 5.42M share offering by selling stockholders